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Abstract 
 
Objective: Ghrelin is an orexigenic peptide hormone involved in the regulation of energy 
homeostasis, food intake and glucose metabolism. Serum levels increase anticipating a meal 
and fall afterwards. Underlying genetic mechanisms of the ghrelin secretion are unknown.  
Methods: Total serum ghrelin was measured in 1501 subjects selected from the population-
based LIFE-ADULT-sample after an overnight fast. A genome-wide association study 
(GWAS) was performed. Gene-based expression association analyses (transcriptome-wide 
association study (TWAS)) were done using MetaXcan.  
Results: In the GWAS, three loci reached genome-wide significance: the WW-domain 
containing the oxidoreductase-gene (WWOX; p=1.80E-10) on chromosome 16q23.3-24.1 
(SNP: rs76823993); the Contactin-Associated Protein-Like 2 gene (CNTNAP2; p=9.0E-9) on 
chromosome 7q35-q36 (SNP: rs192092592) and the Ghrelin And Obestatin Prepropeptide 
gene (GHRL; p=2.72E-8) on chromosome 3p25.3 (SNP: rs143729751). In the TWAS, serum 
ghrelin was negatively associated with RNA expression of the GDNF Family Receptor Alpha 
Like (GFRAL), receptor of the anorexigenic Growth Differentiation Factor-15 (GDF15), (z-
score=-4.288, p=1.81E-05). Furthermore, ghrelin was positively associated with Ribosomal 
Protein L36 (RPL36; z-score=4.848, p=1.25E-06).  
Conclusions: Our findings provide evidence of a functional link between two major players of 
weight regulation, the ghrelin system and the GDF15/GFRAL-pathway. 
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1. Introduction 
 
Ghrelin is a 28-amino-acid peptide hormone synthesized in the stomach.1 Ghrelin binds to its 
receptor, the growth hormone secretagogue receptor 1a (GHSR1a), after being acylated by 
ghrelin-O-acyl-transferase (GOAT).2,3 Ghrelin is secreted in a pulsatile manner and factors 
regulating ghrelin serum levels are circadian rhythm, sex, feeding status, body fat and 
stress.4,5 However, underlying genetic mechanisms of the ghrelin secretion are unknown. 
Ghrelin receptors and GOAT are broadly expressed, including in intestine, pituitary, kidney, 
lung, heart, pancreatic islets, endocrine tissue and the central nervous system (CNS).6 
Accordingly, ghrelin has been shown to be involved in various biological functions. It 
stimulates the hypothalamic pituitary (HP)-adrenal and the growth hormone axes,1 but 
inhibits the HP-gonadal and the HP-thyroid axes (TSH).7,8 In the CNS, ghrelin was shown to 
activate the reward system,9,10 increasing food, drug and alcohol consumption, being 
considered a relevant factor for the development of addiction.10,11 Published evidence 
consistently points to anxiolytic and antidepressant effects and a prominent role in learning, 
memory and neuroprotection.11,12 It increases blood glucose by suppressing pancreatic 
insulin secretion, increases hepatic gluconeogenesis and stimulates gastric motility and 
emptying as well as lipogenesis.5,13 While ghrelin has been implicated in various cancers, its 
precise role in cancer development and progression is unclear.14  
 
Ghrelin increases weight by reducing energy expenditure and increasing appetite and 
thereby food intake.15 The orexigenic (appetite increasing) effect is mediated at hypothalamic 
level by stimulating neurons containing orexigenic neuropeptide Y (NPY) and agouti-related 
protein (AgRP) and by inhibiting neurons containing anorexigenic a-melanocyte-stimulating 
hormone (a-MSH) and cocaine- and amphetamine-regulated transcript (CART).5,16,17 Leptin, 
an important adipocyte-derived anorexigenic hormone, exerts opposite effects on these 
neurons.18 GDF15 is another anorexigenic peptide with a different mode of action.19,20 
GDF15 binds to GFRAL located in the area postrema.21–24 The clinical relevance of the 
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GDF15/GFRAL-pathway, e.g. in mediating metformin’s` metabolic effects, is just being 
recognized.20 There has been almost no information on the association between 
GDF15/GFRAL-pathway and the ghrelin system so far.  
 
Due to its involvement in various auto-regulatory systems, the ghrelin system has been 
identified as a potential drug target for several conditions including tumor cachexia25 and 
addiction with promising results in recent years.26  
 
In order to elucidate genetic mechanisms underlying the ghrelin secretion, a first GWAS of 
total ghrelin in serum and a TWAS were performed, integrating expression quantitative trait 
loci (eQTL) information across various tissues with GWAS results using MetaXcan.27 
 
 
2. Methods 
 
2.1 Study design and subjects 
Subjects were recruited in the framework of the LIFE-Adult study, a population-based cohort 
with 10,000 adults (age range mainly 40-79 years, 400 subjects with an age range of 18-39 
years). Participants were age- and sex-stratified randomly recruited in the city of Leipzig, 
Germany (for details of the study design see).28 Total ghrelin was measured in 1666 
subjects. From these, 165 subjects were excluded due to an incomplete data set, i.e. when 
any of the parameters required for data analyses was missing such as body mass index 
(BMI) or genetic data of sufficiently high quality. Thus, the resulting study population 
comprised 1501 subjects (807 men and 694 women). All participants gave written informed 
consent to take part in the study. The procedures were conducted according to the 
Declaration of Helsinki and approved by the ethics committee of the University of Leipzig 
(registration-number: 263-2009-14122009). 
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2.2 Ghrelin measurements 
Blood samples were collected after an overnight fast between 07:30 and 10:30 h, serum was 
separated by centrifugation and then frozen and stored at -80°C. Ghrelin in serum was 
measured using a radioimmunoassay for total ghrelin (Mediagnost, Reutlingen Germany). 
Sensitivity of the assay was 0.04 ng/mL, mean intra-assay coefficients of variation were 2.7-
4.3%; inter-assay coefficients of variation were between 6.9% and 9.2% for the mean 
expected range of clinical data around 0.88 and 0.97 ng/mL.     
 
2.3 Genotyping, preprocessing and imputation 
Subjects were genotyped with the genome-wide SNP array Axiom Genome-Wide CEU 1 
Array Plate (Affymetrix, Santa Clara, California, USA). Details of genotyping and primary 
quality control of samples and SNPs can be found elsewhere.29 In brief, sample quality 
control included analysis of dishQC, call rate, heterozygosity, sex mismatches, cryptic 
relatedness and for X-chromosomal analysis irregularities of X-Y intensity plots. SNP quality 
control included call rate (≤97%), parameters of cluster plot irregularities as suggested by 
Affymetrix best practice, violation of Hardy-Weinberg equilibrium (p≥10−6 in exact test) and 
plate associations (p≥10−7). In total 4985 (4978) samples and 532875 (13554) SNPs fulfilled 
all quality criteria for autosomal (X-chromosomal respectively) analysis. 
Genotypes of the 1000 Genomes reference phase 3 , version 530 were imputed using 
IMPUTE2 (version v2.3.2)31 after pre-phasing with SHAPEIT (version v2.r837).32 SNPs with 
low imputation quality (IMPUTE info score<0.5) and bad power (minor allele frequency<2%) 
were filtered. A total of 9,868,623 SNPs were considered for analysis.  
 
2.4 GWAS analyses 
6 
 
Ghrelin, covariables and genotype data are available for a total of 1501 samples. Association 
analysis was performed with SNPTEST (version 2.5.2 ). Logarithmized ghrelin levels were 
adjusted for age, sex, alcohol intake, smoking status and logarithmized BMI and an additive 
model of inheritance was assumed. X-chromosomal variants were analyzed assuming total 
X-inactivation. A-value cut-off of 5x10-8 was considered genome-wide significant. 
Independent SNPs were determined by priority pruning applying a linkage disequilibrium cut-
off of r2≥0.5. 
SNPs were comprehensively annotated by an in house pipeline as explained elsewhere.33 In 
brief, annotation comprised nearby genes using Ensemble, LD based look-up of other GWAS 
traits presented in the GWAS Catalog,34 and of expression quantitative trait loci (eQTLs) as 
reported by GTex and own blood data.35 
 
2.5 TWAS Analysis 
For gene-based expression association analyses, we utilized MetaXcan.27 We applied the 
GTEXv7 models, MESA,36 and DGN-model as it was trained by the authors. For this 
analysis, we used the same SNP filter criteria regarding MAF and info-score as in our main 
GWAS. Correction for multiple testing for the number of tested tissue and tested genes was 
done at the FDR 50% level in a hierarchical way considering genes as the unit of interest as 
previously described.37 
 
 
 
 
3. Results 
 
3.1 GWAs analysis 
GWAS was performed in the population-based ‘LIFE-Adult study’. Sample description is 
provided in Table 1. GWA analysis revealed no signs of general inflation of test statistics 
7 
 
(Lambda=1.00). Independent SNPs reached genome-wide significance and could be 
attributed to three distinct genetic loci.  
 
The strongest hit was an intronic variant of the WW-domain containing the oxidoreductase-
gene (WWOX) located on chromosome 16q23.3-24.1 (SNP: rs76823993; MAF=1.7%, 
explained variance 2.4%, p=1.8E-10.) Carriers of the minor allele had lower ghrelin serum 
levels (Fig. 1, Table 2). Six further SNPs in the WWOX gene support the signal (p<E-6) (Fig. 
2).  
 
The second strongest genetic variant reaching genome-wide significance is located on 
chromosome 7q35-q36.1 in the Contactin-Associated Protein-Like 2 gene (CNTNAP2; SNP: 
rs192092592; MAF=1.2%, explained variance 2.0%, p=9.0E-9) (Fig. 1, Table 2). However, 
this SNP is not supported by other variants, requiring future validation. Carriers of the minor 
allele showed lower ghrelin serum levels.  
 
The third genetic variant reaching genome-wide significance was on the Ghrelin And 
Obestatin Prepropeptide (GHRL) gene in the position 3p25.3 itself which is biologically highly 
plausible (SNP: rs143729751; MAF=2.1%, explained variance 1.8%, p=2.72E-8). The SNP is 
in some linkage disequilibrium (LD) with an eQTL of GHRL in blood (r2=0.64). Carriers of the 
minor allele showed lower ghrelin serum levels (Fig. 1, Table 2). 14 hits in 9 different genes 
reached trend significance (Table 2). 
 
3.2 TWAs analysis 
 
In a MetaXcan-analysis, ghrelin serum levels were associated with messenger RNA (mRNA) 
expression of the GFRAL gene in adipose tissue (z-score=-4.288; p=1.81E-05, False-
discovery-rate (FDR)=0.147, number of SNPs used=109). In addition, ghrelin serum levels 
were also associated with messenger RNA (mRNA) expression of the RPL36 gene (z-
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score=4.848; p=1.25E-06, FDR=0.011, number of SNPs used=20) in a variety of tissues 
including cerebellum, whole blood, subcutaneous fat, esophagus mucosa, skeletal muscles 
and transverse colon. That means that a lower expression of GFRAL and a higher 
expression of RPL36 were associated with higher levels of serum ghrelin. Regional 
association plots summarize the evidence of all eQTLs of GFRAL and RPL36 that were used 
to identify the gene-expression association with serum ghrelin (Fig. 3).   
 
 
 
4. Discussion 
 
 
In this GWAS total ghrelin serum levels as trait were investigated. We were able to identify 
three genetic loci reaching genome-wide significance and 14 in 9 genes that showed an 
association with ghrelin serum levels at a trend level. The strongest and best supported hit 
was an intronic variant in the WWOX-gene (p=1.80E-10). WWOX spans the second most 
common fragile site FRA16D and encodes for a 414-amino acid protein that contains two 
WW domains. WW structures are known to be involved in protein-protein 
interactions. WWOX is highly expressed in hormonally regulated tissues (testis, prostate, and 
ovary).38  
 
The second strongest hit was an intronic variant in the CNTNAP2-gene (p=9.0E-9). It is the 
longest gene in the human genome, encompassing almost 1.5% of chromosome 7. It 
encodes for the protein Contactin-Associated Protein-Like 2 (CASPR2). CASPR2 is part of 
the neurexin superfamily and functions as cell adhesion molecules and receptors in the 
central nervous system of vertebrae. It is mainly localized at the juxtaparanodes of 
myelinated axons and mediates interactions between neurons and glia during nervous 
system development. It is also involved in localization of potassium channels within 
differentiating axons.39 
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The third hit was in the GHRL-gene itself (p=2.72E-8). GHRL encodes for a 117-amino acid 
preprohormone called preproghrelin. From this, the 28-amino acid des-acyl ghrelin is spliced, 
as well as obestatin and the C-terminal ending of the preproghrelin, called C-ghrelin. 
Obestatin was originally believed to be a ghrelin-antagonist, but more recent evidence has 
questioned this and both its exact function and the function of C-ghrelin remain unclear.5  
 
All candidate genes are functionally highly plausible: 
 
When looking at the biological functions coded by WWOX and CNTNAP2, there is a striking 
overlap with functions of ghrelin, mainly concerning processes in the CNS. Both WWOX and 
CNTNAP2 seem to be involved in neuronal development, branching and maturation.40,41 
CNTNAP2 is involved in language processing and development in both animals and humans 
and a multitude of studies shows mental retardation and speech impairment in children with 
genetic aberrations in both genes as well as strong associations with epilepsy.42 This is of 
relevance, as ghrelin has been consistently shown to exert neuroprotective and 
anticonvulsant effects and promote neurogenesis, mainly in the hippocampus.11 WWOX and 
CNTNAP2 are associated with Alzheimer’s disease, with both being identified as risk loci for 
late onset Alzheimer disease (LOAD) in Alzheimer’s disease GWAs and GWA-meta-
analyses.43,44 
 
Genetic variants of WWOX have been linked to obesity, type 2 diabetes, high fasting glucose 
and high body-mass-index,45 thus showing a strong overlap with ghrelin function. A loss of 
function of WWOX has been documented in many tumor entities46 and WWOX has been 
shown to be a tumor-suppressor gene.47 Ghrelin is expressed in many cancers like renal cell 
carcinoma, pancreatic cancer, thyroid cancer, lung cancer, breast cancer, prostate cancer, 
gastric cancer and colorectal carcinoma. Its role in cancer growth and progression is being 
controversially discussed, e.g. due to a presumably dosage-dependent effect on tumor 
growth.14 
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CNTNAP2 has been repeatedly linked to psychiatric diseases. Especially for autism, there is 
broad evidence suggesting an involvement of CNTNAP2 in the pathogenesis of this 
disease.48,49 CNTNAP2 has also been shown to be associated with schizophrenia, bipolar 
disorder and major depression.39,50 Ghrelin has been consistently shown to exert 
antidepressant and anxiolytic properties in animals models and the ghrelin system has been 
repeatedly shown to be altered in patients suffering from major depression.11 Also the fact 
that auto-antibodies against CASPR2, CNTNAP2’s gene product, can cause autoimmune-
encephalitis often presenting with schizophrenia-like symptomatology is in line with 
CNTNAP2’s involvement in psychiatric illnesses.51 
 
In a TWAS using MetaXcan,27 exploiting tissue-specific expression quantitative trait loci 
(eQTLs), a negative association between the expression of the GFRAL gene in 
subcutaneous adipose tissue and ghrelin serum levels was found. The GDF15/GFRAL-
system has been identified recently. In 2017, four groups reported that brain-stem located 
GFRAL, detected in 2005 as an orphan receptor,52 is the receptor for GDF15, requiring 
receptor tyrosine kinase (RET) as a co-receptor.21–24 GDF15, also known as Macrophage 
Inhibitory Cytokine-1 (MIC-1), had been identified in 2007 as a peptide mediating 
anorectic/cachectic effects.19 Its relevance is just being recognized: For example, weight loss 
associated with metformin, the worldwide most prescribed antidiabetic, was shown to 
correlate with increase of GDF15 and to depend on the integrity of the GDF15/GFRAL 
system.20 
 
Our findings suggest that increased expression of GFRAL in subcutaneous adipose tissue 
has a directional effect on reducing ghrelin serum levels. This is very plausible, as the 
GDF15/GFRAL-system and the ghrelin system have opposing effects in the organism, not 
only in energy metabolism and appetite control. A further parallel between ghrelin and 
GDF15, is that both are produced in times of stress.5,53,54 Here, too, they have opposite 
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effects on appetite and food intake, being in line with a metabolic interaction also in stress. In 
addition, very recently, GDF-15 was shown to have pro-emetic effects,55 while ghrelin is 
known to be a strong anti-emetic agent and promoter of gastric motility.56 This further points 
to an antagonistic relationship between ghrelin and GDF-15/GFRAL. Finally, for ghrelin and 
GDF15 both tumor-growth promoting and -inhibiting effects are being discussed.14,57  
 
Yet, while the presence of GFRAL-mRNA in subcutaneous adipose tissue is a robust and 
replicated finding,23,27 its biological relevance in subcutaneous tissue remains to be 
elucidated, since its protein product, the GFRAL-receptor, has been detected so far only in 
the brain stem.22,23  
 
So far, no data exists linking GFRAL and ghrelin and only very scarce data studying GDF15 
and ghrelin. Here, a non-peptidergic ghrelin receptor agonist did not affect GDF15 in mice.58 
 
A positive association with ghrelin serum levels was found in the TWAS also for mRNA 
expression levels of the RPL36 gene in various tissues including cerebellum, whole blood, 
subcutaneous fat, esophagus mucosa, skeletal muscles and transverse colon. RPL36 is a 
subunit of the 60S ribosomal protein and as such involved in protein synthesis and cell 
proliferation.59 This finding is biologically plausible as ghrelin functions as an anabolic 
hormone. Furthermore, RPL36 has been implicated like ghrelin in carcinogenesis with a so 
far unclear role.59  
 
Limitations of this study are the relatively small case sample for a GWAS and that no 
replication cohort was available.  
 
In conclusion, we identified three functionally plausible genetic loci reaching genome-wide 
significance in the GWAS of ghrelin serum levels. Furthermore, performing a TWAS, we 
could link the ghrelin system with the GDF15/GFRAL-system, suggesting an interaction 
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between these systems having opposite effects on appetite control and energy homeostasis. 
Further research based on these findings is warranted as they might lead to a better 
understanding of and innovative treatment approaches for metabolic, oncological and 
neuropsychiatric diseases.  
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Figures 
 
 
 
 
Fig. 1: Manhattan plot showing the SNP associations for total ghrelin serum levels. 
The limit for genome-wide significance (p=5.0x10-8) is displayed as line. 
 
 
 
21 
 
 
 
Fig. 2: Regional association (RA) plots of three GWAS hits. The lead SNP is colored 
blue, and the other SNPs are colored according to their LD with the lead SNP (using 1000 
Genomes Phase 3, Europeans only). (A) RA plot for rs143729751 and GHRL at cytoband 
3p25.3. (B) RA plot for rs192092592 and CNTNAP2 at 7q35. (C) RA plot for rs76823993 and 
WWOX at 16q23.1. 
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b) 
 
 
Fig. 3: Regional association plots of GFRAL (a) and RPL36 (b) showing all eQTL-SNPs 
included in the gene expression model. It illustrates that many only nominal association of 
SNPs with ghrelin contribute jointly to the significant gene-level association of GFRAL (a) 
respectively RPL36 (b) with ghrelin. 
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Tables 
 
 
Table 1: Description of the study sample  
 
 
a A Kolmogorov-Smirnov-Test was performed in order to assess normal distribution. Because 
of non-normal distribution of the dependent variables according to these results, a Mann-
Whitney-U-test was applied to compare ghrelin serum levels (Z=-11.13), age (Z=-0.29) and 
BMI values (Z=-4.19) between sexes. b A chi2 test for two-by-two tables was used.   
 
 
 
 
 
 
 
 
 
 
 Total sample 
(n=1501) 
Males (n=807) 
(53.8%) 
Females 
(n=694) (46.2%) 
 p-value 
Age, years, mean (SD) 57.9 (15.2) 57.5 (15.5) 58.3 (14.7) 0.78a 
BMI, kg/m2, mean (SD) 27.1 (4.5) 27.4 (4.0) 26.7 (4.9) <0.001***a 
Non-smokers, n (%) 
(n=1457) 
1235 (84.8%) 651 (82.4%) 
(n=790) 
584 (87.6%) 
(n=667) 
0.006**b 
Ghrelin serum, pg/ml, 
mean (SD) 
927.6 (450.6) 812.9 (306.7) 1061.0 (545.0) <0.001***a 
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Table 2: Loci showing genome-wide significance and trend significance for total ghrelin serum levels 
 
 
Loci showing genome-wide significance (P <5E-6) 
            
SNP Cytoband Chr Position 
Candidate 
genes 
Impute Info 
score 
Effect 
allele 
Other 
allele 
MAF 
(Effect allele) 
Beta (CI) 
(Effect allele) 
P η
2 
rs76823993 16q23.1 16 78740996 WWOX 0.927 A C 0.017 -0.382 (-0.5 - -0.27) 1.80E-10 0.024 
rs192092592 7q35 7 147356108 CNTNAP2 0.859 G A 0.012 -0.439 (-0.59 - -0.29) 9.00E-9 0.019 
rs143729751 3p25.3 3 10330266 GHRL 0.952 T G 0.021 -0.299 (-0.4 - -0.19) 2.72E-8 0.018 
 
 
Loci showing trend significance (P <1E-6) 
            
rs139359241 9q33.1 9 121992761 BRINP1 0.834 A G 0.015 -0.36 (-0.5- -0.24) 6.82E-8 0.017 
rs117196347 16q23.1 16 78720394 WWOX 0.988 T C 0.026 -0.25 (-0.34- -0.16) 1.26E-7 0.017 
rs118158533 16q23.1 16 78720391 WWOX 0.949 C G 0.016 -0.32 (-0.44- -0.20) 1.30E-7 0.017 
rs74483218 7p14.1 7 38031039 SFRP4 0.902 A G 0.015 -0.35 (-0.48- -0.22) 1.37E-7 0.016 
rs199653320 5q12.3 5 65124780 NLN 0.997 AC A 0.010 -0.40 (-0.55- -0.25) 1.59E-7 0.016 
rs139200008 16q23.1 16 78734010 WWOX 0.917 CTA C 0.026 -0.25 (-0.35- -0.16) 1.71E-7 0.016 
rs112426408 1q44 1 244052447 AKT3 0.87 G A 0.029 -0.23 (-0.33- -0.15) 2.68E-7 0.016 
rs77563704 5q14.3 5 91845530 RP11-133 0.936 A C 0.050 -0.17 (-0.24- -0.11) 3.92E-7 0.015 
rs187860960 20p12.3 20 5920093 TRMT6 0.84 T C 0.025 -0.25 (-0.35 - -0.15) 6.58E-7 0.015 
rs138296128 5q12.3 9 36885124 PAX5 0.827 A C 0.012 -0.38 (-0.53- -0.23) 7.60E-7 0.015 
rs113194124 7p14.1 7 38014091 SFRP4 0.965 T C 0.027 -0.23 (-0.33- -0.14) 7.94E-7 0.014 
rs80240706 1q44 1 243997795 AKT3 0.901 T C 0.027 -0.23 (-0.32- -0.14) 8.87E-7 0.014 
rs142653572 11p11.2 11 44370951 ALX4 0.818 T C 0.011 -0.39 (-0.54- -0.23) 9.21E-7 0.014 
rs142224718 4q24 4 102643916 BANK1 0.900 C T 0.011 -0.37 (0.53- -0.23) 9.64E-7 0.014 
SNP: Single nucleotide polymorphism, Chr: Chromosome, Info: information quality of imputed SNPs according to IMPUTE 2, Min/Maj: Minor allele/major allele, MAF: Minor allele frequency, Beta 
(CI): Beta coefficient (confidence interval), η
2
= explained variance, WWOX: WW-domain containing oxiduoreductase-gene CNTNAP 2: Contactin Associated Protein Like 2, GHRL: Ghrelin And 
Obestatin Prepropeptide, BRINP1: BMP/retinoic acid inducible neural specific 1, SFRP4: Secreted frizzled related protein 4, NLN: Neurolysin, AKT3: AKT Serine/Threonine Kinase 3, RP11-133: 
long non-coding RNA, manual annotation from Havana project, TRMT6: TRNA Methyltransferase 6, PAX 5: Paired Box 5, ALX4: ALX Homeobox 4, BANK1: B Cell Scaffold Protein With Ankyrin 
Repeat     
